Artificial Intelligence - INFORMS
Artificial Intelligence - INFORMS
Artificial Intelligence - INFORMS
Healthcare
by Jingmei Yang
SECOND PRIZE in OR/MS Tomorrow Student Writing Competition 2019
Jingmei Yang is a Ph.D. student in Industrial Engineering at the University of Texas at
Arlington.
The future of the healthcare industry has never been as bright as today. The application of
Artificial Intelligence (AI) has made remarkable progress in its impact across a range of
medical applications including drug discovery, remote patient monitoring, medical
diagnostics, risk management, virtual assistants and hospital management. Improvements in
accuracy and efficiency are made possible by innovations in deep neural networks and
high-end computational resources in combination with increasing availability of medical
data. In this report, we summarize some significant AI innovations in healthcare followed
by a discussion on future challenges and opportunities.
Convolution network for skin diseases detection, Source: Esteva et al. (2017), picture
courtesy of the authors.
AI can be used for retinal disease diagnosis. A research team in DeepMind developed an
innovative framework that investigates eye scans from routine clinical practice. In a paper
published in Nature, De Fauw et al. (2018) demonstrated that an AI system is capable of
automatically identify- ing retinal diseases in only a minute. Additionally, the system can
classify patients based on their severity and redistribute medical resource to the patients
most in need of urgent care. This prioritization attempts to reduce the long delays between
scan and treatment resulting from the complexity of interpreting the Optical Coherence
Tomography images and the reducing numbers of qualified interpreters. This framework
can make referral recommendations for over 50 sight-threatening retinal diseases at a level
comparable to clinical experts and has great potential for preventing patients with diabetic
retinal disease from sight loss.
Retinal disease diagnosis and referral suggestions framework. Source: De Fauw et al.
(2018), picture courtesy of the authors.
The neural decoding process with AI, picture taken from Anumanchipalli et al., (2019).
AI in Radiology. Recently there has been a massive amount of publications using deep
learning to process medical imaging such as image denoising, segmentation, and super-
resolution. Of particular interest is a research team from the University of Texas at
Southwestern Medical Center (UTSW) lead by Dr. Steve Jiang. Due to increasing treatment
modalities in radiation therapy, treatment planning is complicated and time-consuming for
dosimetrists. With an effort to cut down on the planning time while maintaining quality, the
team from UTSW built a convolutional neural network to predict the radiation therapy dose
for prostate cancer patients (Nguyen et al., 2019). By mapping the patient’s contours into
local and global features, the model is empowered to predict a dose distribution with
impressive accuracy. If equipped with this dose prediction model in clinical practice,
physicians can use the prediction as a preliminary plan and cooperate with dosimetrists for
further tailoring, making the planning workflow smooth and efficient.
U-net architecture with additional CNN layers used for dose prediction. Source: Nguyen et
al. (2019), picture courtesy of the authors.
Deep learning is often treated as a black box; its features and parameters are challenging to
understand and interpret in a healthcare setting. Not being able to explain the internal
mechanics of a model is a barrier for the broad adoption of AI since clinical practitioners
place trust heavily on interpretability. As such, researchers have worked on developing
interpretable AI systems. Hopefully, this work will make AI systems easier to understand
and adopt in practice. Data heterogeneity is another challenge. As shown in the study led by
Zech et al. (2018), image data from different hospitals, vendors of imaging modalities and
scanners or reconstruction conditions has significant influence on the model performance.
Acquiring a training dataset from diverse settings, nonidentical populations, or multiple
institutions is beneficial to overcome this problem. Patients’ privacy is also a concern.
Unlike other domains, the healthcare industry handles a lot of sensitive patients’
information. How to balance the usage of all the data and control the infringement of
privacy of patients requires care and effort when developing models.
External validation is necessary for AI to prove its promise. All AI-based models need to be
validated with clinical trials to test its practical value and performance in a real-world
setting. If clinical performance is validated and interpretability of the models are enhanced,
AI has the potential to positively impact clinical practice with better performance and
increased efficiency.
1. Anumanchipalli, G.K., Chartier, J., and E.F. Chang (2018). Speech synthesis from
neural decoding of spoken sentences. Nature, 568(7753):493-498.
2. De Fauw, J., Ledsam, J.R., Romera-Paredes, B., Nikolov, S., Tomasev, N., Blackwell,
S., Askham, H., Glorot, X., O’Donoghue, B., Visentin, D., et al. (2018). Clinically
applicable deep learning for diagnosis and referral in retinal disease. Nature Medicine,
24(9):1342- 1350.
3. Esteva, A., Kuprel, B., Novoa, R.A., Ko, J., Swetter, S.M., Blau, H.M., and S. Thrun
(2017). Dermatologist- level classification of skin cancer with deep neural networks.
Nature, 542(7639):115-118
4. Nguyen, D., Long, T., Jia, X. Lu, W., Gu, W., Iqbal, Z., and Steve Jiang (2019). A
feasibility study for predicting optimal radiation therapy dose distributions of prostate
cancer patients from patient anatomy using deep learning. Scientific reports, 9(1):1076.
5. Poplin, R., Varadarajan, A.V., Blumer, K., Liu, Y., McConnell, M.V., Corrado, G.S.,
Peng, L., and D.R. Webster (2018). Prediction of cardiovascular risk factors from retinal
fundus photographs via deep learning. Nature Biomedical Engineering, 2(3):158-164.
6. Rogers, H.W., Weinstock, M.A., Feldman, S.R., and B.M. Coldiron (2015). Incidence
estimate of non- melanoma skin cancer (keratinocyte carcinomas) in the U.S. population,
2012. Jama Dermatology, 151(10):1081-1086.